Race-Related Germline Polymorphisms in Key Androgen Transport Genes Among Black (B) and White (W) Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Treated with Abiraterone Acetate plus Prednisone: Single Nucleotide Polymorphism Analyses from the Abi Race Trial

Megan A McNamara1, Susan Halabi1, Elisabeth I. Heath2, A. Oliver Sartor3, Guru Sonpavde4, William R. Berry5, Patrick Healy5, Carolyn Winters1, Colleen Riggan1, Monika Anand1, Julie Kephart1, Matthew I. Milowsky6, Mark T. Fleming7, Tian Zhang1, Rhonda L. Bitting, Michael R Harrison1, Jennifer A. Freedman1, Deborah Bruner, Andrew J. Armstrong1, Daniel J. George1.

1Duke Cancer Institute, Duke University, Durham, NC; 2Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI; 3Tulane Medical School, New Orleans, LA; 4Dana-Farber Cancer Institute, Boston, MA; 5Duke University School of Medicine, Raleigh, NC; 6UNC School of Medicine, Chapel Hill, NC; 7Virginia Oncology Associates, US Oncology Research, Norfolk, VA; 8Wake Forest University Health Sciences, Winston Salem, NC; 9Winship Cancer Institute at Emory University, Atlanta, GA

Background: Black (B) men have higher incidence, aggressiveness, and mortality from prostate cancer (PC) than men of other racial groups, even after accounting for differences in social and behavioral determinants of health. Germline polymorphisms in androgen metabolism genes, some of which vary in relative allelic frequency by ancestry, have prognostic value in regards to the time to development of castrate resistant prostate cancer (CRPC). The solute carrier organic anion (SLCO) genes are involved in steroid hormone transport across plasma membranes, potentially regulating the intracellular concentrations of androgen precursors that may account for relatively high intracellular androgen levels in CRPC. Single nucleotide polymorphisms (SNPs) in SLCO2B1 and SLCO1B3 have been correlated with a significantly shorter time to CRPC. Additionally, since abiraterone has a steroid backbone in its structure, SLCO2B1 may regulate the efficacy of abiraterone.

Methods: We conducted a prospective, multicenter, parallel group study of abiraterone acetate (AA) plus prednisone (P) in 50 B and 50 white (W) men with mCRPC, self-identified by race (Abi Race (NCT01940276). All patients received AA 1000 mg/D and P 10 mg/D (AAP) until disease progression or adverse events (AE). The primary objective was radiographic progression-free survival (rPFS); key secondary endpoints include PSA kinetics and safety. Exploratory analyses include SNP, metabolomics and hormonal differences by race.

Results: Median rPFS for B and W pts was 16.8 months (mo) in each. PSA PFS varied by race; median PSA PFS for B and W pts were 16.6 and 11.5 mo. For SLCO2B1 SNP rs12422149, 91.9% (n=34/37) of W pts were genotype BB and 8.1% (n=3/37) were AB, while 69.8% (n=30/43) of B pts were genotype BB, 27.9% (n=12/43) were AB, and 2.3% (n=1/43) were AA. The racial distribution of SLCO1B3 SNP rs4149117 was 64.9% (n=24/37) BB, 32.4% (n=12/37) AB, and 2.7% (n=1/37) AA among W pts, compared to 20.9% (n=9/43) BB, 51.2% (n=22/43) AB, and 27.9% (n=12/43) AA among B pts.

Conclusions: We found that self-reported B with mCRPC were much more likely to have one or more A alleles in SLCO2B1 SNP rs12422149 than W men. Similarly, 28% of B men were found to have the AA genotype in SLCO1B3 SNP rs4149117, compared to < 5% of W, suggesting that ancestry correlates with genetic differences in these key androgen transport genes. Confirmation of these findings is planned in the similarly structured PANTHER study of AA plus apalutamide (NCT03098836). We will also use the combined Abi Race and PANTHER cohorts to perform an analysis of these SNPs, and others that are known to vary in minor allele frequency by ancestry and have previously been shown to associate with response to ADT, in order to determine if these SNPs also associate with response to second generation androgen-directed therapies.

Funding Acknowledgement: Janssen Scientific Affairs, LLC provided funding support and study drug
Conflict of Interest:

Megan A McNamara

**Research Funding** – Agensys (Inst); Bayer (inst); Clovis Oncology (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)

**Travel, Accommodations, Expenses** - Agensys; Clovis Oncology

Susan Halabi

**Consulting or Advisory Role** - Bayer; Eisai; Tokai Pharmaceuticals

**Travel, Accommodations, Expenses** - Bayer

Elisabeth I. Heath

**Honoraria** - Bayer; Dendreon; Sanofi

**Consulting or Advisory Role** - Agensys

**Speakers' Bureau** - Sanofi

**Research Funding** - Agensys (Inst); Celgene (Inst); CellDex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seattle Genetics (Inst); Tokai Pharmaceuticals (Inst)

A. Oliver Sartor

**Consulting or Advisory Role** - Advanced Accelerator Applications; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Sanofi

**Research Funding** - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst)

**Travel, Accommodations, Expenses** - AstraZeneca; Bayer; Bellicum Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Progenics; Sanofi; Tokai Pharmaceuticals

Guru Sonpavde

**Honoraria** - UpToDate

**Consulting or Advisory Role** - Agensys; Amgen; Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Janssen; Merck; Novartis; Pfizer; Sanofi

**Speakers' Bureau** - Clinical Care Options/NCCN; Onclive; Physician Education Resource; Research to Practice

**Research Funding** - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst)

**Other Relationship** - AstraZeneca; Boehringer Ingelheim
William R. Berry
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Medivation

Patrick Healy
No Relationships to Disclose

Carolyn Winters
No Relationships to Disclose

Colleen Riggan
No Relationships to Disclose

Monika Anand
No Relationships to Disclose

Julie Kephart
No Relationships to Disclose

Matthew I. Milowsky
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech

Mark T. Fleming
Employment - Virginia Oncology Associates
Speakers' Bureau - Genentech; Medivation/Astellas
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas

Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi

Speakers' Bureau - Exelixis

Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)

Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)

Travel, Accommodations, Expenses - Acerta Pharma

Rhonda L. Bitting
Research Funding - Merck (Inst)

Michael R Harrison
Consulting or Advisory Role - Bayer; Exelixis; Genentech; Sanofi

Speakers' Bureau - Genentech

Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Genentech; Medivation/Astellas; Pfizer

Jennifer A. Freedman
No Relationships to Disclose

Deborah Bruner
No Relationships to Disclose

Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi

Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi

Speakers' Bureau - Bayer; Dendreon; Sanofi

Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)

Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)

Travel, Accommodations, Expenses - Bayer; Dendreon; Janssen Biotech; Medivation; Sanofi
Daniel J. George

**Honoraria** - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi

**Consulting or Advisory Role** - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi

**Speakers' Bureau** - Bayer; Exelixis; Sanofi

**Research Funding** - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)

**Travel, Accommodations, Expenses** - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer